JANX Q4 2025 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

-$1M-13.5% margin

Operating Income

-$42M-538.1% margin

Net Income

-$32M-405.4% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$55M

Stock-Based Comp.

-$31M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$45M

Stockholders' Equity

$957M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	-$1M	$0	—
Operating Income	-$42M	-$29M	-46.1%
Net Income	-$32M	-$20M	-58.0%